SRGA Insider Trading Activity and SEC Form 4 Filings
SRGA insider trading summary
No open-market insider purchases or sales of Surgalign Holdings, Inc. (SRGA) have been reported on SEC Form 4 in the past 12 months.
Latest SRGA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 18, 2022 | David Lyle | Chief Financial Officer | Buy | $100K (19,000 @ $5.26) |
| Feb 15, 2022 | Terry M. Rich | President and CEO | Buy | $200K (434,784 @ $0.46) |
| Feb 15, 2022 | William Scott Durall | Chief Commercial Officer | Buy | $100K (217,391 @ $0.46) |
| Aug 16, 2021 | Thomas McEachin | Director | Buy | $21K (20,000 @ $1.03) |
| Aug 13, 2021 | Terry M. Rich | President and CEO | Buy | $9K (10,100 @ $0.91) |
| Aug 12, 2021 | Nicholas J Valeriani | Director | Buy | $52K (55,000 @ $0.95) |
| Aug 12, 2021 | Terry M. Rich | President and CEO | Buy | $344K (365,645 @ $0.94) |
| Aug 11, 2021 | Terry M. Rich | President and CEO | Buy | $654K (702,956 @ $0.93) |
| Feb 1, 2021 | Pawel Lewicki | Director | Buy | $3.0M (2,000,000 @ $1.50) |
| Feb 1, 2021 | Stuart F. Simpson | Director | Buy | $500K (333,333 @ $1.50) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.